The immunocompromised patients who have uncontrolled diabetes, transplants, or long-term corticosteroid therapy are the ones who contract mucormycosis the most frequently, but it can also affect those who have been injured, have pathology, or use injectable drugs. The study summarises the consequences, diagnosis, and prevention of mucormycosis in COVID-19-positive hospitalized diabetic patients, as well as the ramifications of the pandemic. Only occurrences or case series reports with appropriate information regarding risk factors, clinical presentation, course, diagnosis, therapy, and prognosis were included in this research because it was conducted using material found on PubMed. We identified eight patients with pulmonary Mucormycosis and six patients with rhino-orbital-cerebral disease. Despite the fact that 10 (71%) of the patients were males with a median age of 58.5 years (IQR 38-79) and 29% of them were females with a median age of 46.5 years, 8 (8/14, or 57% of the patients) had risk indicators for severe COVID-19 (IQR 32-61). Co-infection is prevented and controlled by using a sterile mask, avoiding touching of the nose, eye mouth, control over steroid medication, and controlling diabetes and other conditions in an exceedingly regulated manner.